US Patent

US8569328 — Compositions and methods comprising tilidine or related compounds and dextromethorphan

Method of Use · Assigned to Antecip Bioventures II LLC · Expires 2033-10-29 · 7y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects compositions and methods that combine dextromethorphan with a compound that inhibits the cytochrome P450 isozyme CYP2D6, such as tilidine.

USPTO Abstract

Pain and/or neurological disorders may be treated by administering a therapeutically effective amount of dextromethorphan and a therapeutically effective amount of a compound such as tilidine that inhibits the cytochrome P450 isozyme CYP2D6, to a person in need thereof. The two compounds may be administered separately, or in a single dosage form or composition as described herein.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3419`	—

Patent Metadata

Patent number: US8569328
Jurisdiction: US
Classification: Method of Use
Expires: 2033-10-29
Drug substance claim: No
Drug product claim: Yes
Assignee: Antecip Bioventures II LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.